Celgene Corporation (CELG)
-NasdaqGS 123.64 
0.20(0.16%) May 23, 4:00PM EDT|After Hours
:
123.64 0.00 (0.00%) May 23, 7:06PM EDT
| Prev Close: | 123.44 |
|---|
| Open: | 121.95 |
|---|
| Bid: | 114.00 x 100 |
|---|
| Ask: | 123.95 x 300 |
|---|
| 1y Target Est: | 134.22 |
|---|
| Beta: | 0.92 |
|---|
| Next Earnings Date: | 25-Jul-13 |
|---|
| Day's Range: | 120.55 - 124.97 |
|---|
| 52wk Range: | 58.53 - 131.82 |
|---|
| Volume: | 2,370,746 |
|---|
| Avg Vol (3m): | 3,213,210 |
|---|
| Market Cap: | 51.57B |
|---|
| P/E (ttm): | 37.61 |
|---|
| EPS (ttm): | 3.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Featured on Yahoo! Finance
Headlines
- 4 Healthcare Stock Stories Prescribed For Investorsat Wall St. Cheat Sheet(Thu, May 23)
- NPS Pharma Prices OfferingZacks(Thu, May 23)
- Final Glance: Biotechnology companiesAP(Thu, May 23)
- Amgen Stock Checkup for Mayat Motley Fool(Thu, May 23)
- Midday Glance: Biotechnology companiesAP(Thu, May 23)
- 5 Stocks Raising The Drugs Industry Higherat TheStreet(Thu, May 23)
- Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic CancerBusiness Wire(Thu, May 23)
- Jim Cramer: Buy Biogen Idec, Celgene, Clean Harbors, and This Stockat Wall St. Cheat Sheet(Thu, May 23)
- McDonald’s Initiates a Dividend, Seagate Gets An Upgrade, and 3 More Hot Stocksat Wall St. Cheat Sheet(Thu, May 23)
- Early Glance: Biotechnology companiesAP(Thu, May 23)
- Stocks to Watch: Hewlett-Packard, Pacific Sunwear, Ralph Laurenat The Wall Street Journal(Thu, May 23)
- InPlay: Celgene announces U.S. FDA grants priority review for ABRAXANE sNDA in advanced pancreatic cancerBriefing.com(Thu, May 23)
- Bristol-Myers, Jazz Pharmaceuticals Lead Pharma Rallyat Investor's Business Daily(Wed, May 22)
- Stocks Reverse Lower On Fears That Fed May Pare Easingat Investor's Business Daily(Wed, May 22)
- Gilead's Sofosbuvir under European ReviewZacks(Wed, May 22)
Key Statistics
| Forward P/E (1 yr): | 17.92 |
|---|
| P/S (ttm): | 9.04 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.75 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.43 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 0.96 |
|---|
Business Summary
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries.
View More